1. Home / Clinical Research

Ongoing Clinical Trial Studies

Novo Nordisk Trial

Sponsor: Novo Nordisk

Protocol: NN9838-4942

The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease.

Open for Enrollment

Travere Trial

Sponsor: Travere

Protocol: TVTX-RE021-204

A multicentered, single-group phase 2, exploratory, open-label study to investigate safety and effect of sparsentan in combination with sodium glucose cotransporter-2 (SGLT2) inhibition in the treatment of adult participants with IDA nephropathy (IGAN)

Open for Enrollment

Vera Therapeutics Trial

Sponsor: Vera Therapeutics

Protocol: VT-001-0050

A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN).

Open For Enrollment

Vertex Pharmaceuticals Incorporated Trial

Sponsor: Vertex

Pharmaceuticals Incorporated

Protocol: VX21-147-301

A Phase 2/3 Adaptive, Double-blind, PlaceboControlled Study to Evaluate the Efficacy and Safety of VX- 147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease Vertex Study Number: VX21-147-301 IND Number: 141671.

Open for Enrollment

Vertex Pharmaceuticals Incorporated Trial

Sponsor: Vertex Pharmaceuticals Incorporated

Protocol: VX19-NEN-801

A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin.

Open for Enrollment

Shionogi Trial

Sponsor: Shionogi

Protocol: ACTIV-2D/A5407

A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S- 217622 compared with placebo in non-hospitalized participants with COVID-19.

Open for Enrollment

AstraZeneca AB Trial

Sponsor: AstraZeneca AB

Protocol: D7000C00001 SuperNova

A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment

Closed For Enrollment

Contact Research Team Member

contact search image

How to Refer to a Clinical Research Trial

Please fill our following information:

RMA research Staff member will get back within next 7 business days